Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial
MM Costantine, K Cleary, MF Hebert, MS Ahmed… - American journal of …, 2016 - Elsevier
Background Preeclampsia complicates approximately 3–5% of pregnancies and remains a
major cause of maternal and neonatal morbidity and mortality. It shares pathogenic
similarities with adult cardiovascular disease as well as many risk factors. Pravastatin, a
hydrophilic, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor, has been shown in
preclinical studies to reverse various pathophysiological pathways associated with
preeclampsia, providing biological plausibility for its use for preeclampsia prevention …
major cause of maternal and neonatal morbidity and mortality. It shares pathogenic
similarities with adult cardiovascular disease as well as many risk factors. Pravastatin, a
hydrophilic, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor, has been shown in
preclinical studies to reverse various pathophysiological pathways associated with
preeclampsia, providing biological plausibility for its use for preeclampsia prevention …